Results 31 to 40 of about 32,676 (224)

Rivaroxaban Attenuates the Cardiovascular PAR1-Related Inflammation, Fibrosis and Atherogenicity in Experimental Hypertensive/ Hypercholesterolemia Rat Model [PDF]

The Egyptian Journal of Histology
Introduction: Hypertension and hypercholesterolemia serve as a predisposing component for cardiovascular disorders. As an oral anticoagulant, Rivaroxaban is used to preclude and eliminate venous thrombosis, atrial fibrillation and coronary artery ...
Hanan Shamardl, Eman Hussien, Marwa Sofi, Sawsan Sadik   +3 more
doaj   +1 more source

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Pharmaceutics
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects.
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhichun Gu, Qianzhou Lv, Xiaoye Li   +9 more
doaj   +1 more source

The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

Applied Sciences, 2021
Interindividual variabilities between patients taking the anticoagulant rivaroxaban are a result of hepatic metabolism by CYP 450 enzymes. The objective of this study was to evaluate the impact of rivaroxaban on CYP4F2 and transcription factors’ activity
Ieva Ciapiene, Vacis Tatarunas, Agne Giedraitiene, Vaidotas Zvikas, Valdas Jakstas, Audrone Veikutiene, Ugne Meskauskaite, Ugne Venckyte, Audrius Pukalskas, Vaiva Lesauskaite   +9 more
doaj   +1 more source

Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study

American Journal of Hematology, EarlyView.
ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim, Radhika Gangaraju, Omid Jafari, Zihan Yang, Joyce W. T. Tiong, Elizabeth C. L. Chiang, Shengling Ma, Jun Y. Jiang, Justine Ryu, Barbara D. Lam, Mrinal Ranjan, Ang Li   +11 more
wiley   +1 more source

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

TH Open, 2017
Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer.
Walter Ageno, Lorenzo G. Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Alexander G. G. Turpie   +8 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundVenous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for ...
Jay M. Margolis, Steven Deitelzweig, Jeffrey Kline, Oth Tran, David M. Smith, Brahim Bookhart, Concetta Crivera, Jeff Schein   +7 more
doaj   +1 more source

Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. [PDF]

, 2017
OBJECTIVES Treatment of epistaxis in patients on anticoagulants is challenging and associated with higher admission rates and longer hospital stays compared with patients without anticoagulation. However, there is little information about epistaxis in
Sauter, Thomas, Hautz, Wolf, T.C. Sauter, A.K. Exadaktylos, Krummrey, G, M.E. Ricklin, Hegazy, K, Borner, U, M. Nagler, W.E. Hautz, K. Hegazy, G. Krummrey, Ricklin, Meret, U. Borner, Nagler, Michael, Exadaktylos, Aristomenis   +15 more
core   +1 more source